Activity Overview
Ovarian cancer remains one of the most lethal gynecologic malignancies, with high recurrence rates and frequent progression to platinum-resistant disease. Although advances such as PARP inhibitors, antibody-drug conjugates, and immunotherapy have expanded treatment options, clinicians continue to face challenges in biomarker testing, treatment sequencing, and the management of therapy-related toxicities. To address these gaps, this program uses an interactive, case-based symposium format to review key clinical trial data and their application in practice.
This educational activity is an archive of the live presentation held in conjunction with the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer on April 13, 2026, in San Juan, Puerto Rico.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward medical oncologists, radiation oncologists, pathologists, OB/GYNs, advanced practice providers, nurses, pharmacists, trainees, and other health care providers involved in the management of patients with ovarian cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe germline and somatic testing strategies to guide treatment approaches in patients with ovarian cancer
- Characterize the mechanistic rationale of emerging novel therapeutic strategies for the treatment of ovarian cancer
- Integrate recent clinical trial evidence into individual treatment plans for patients with ovarian cancer
- Develop effective strategies to monitor for, identify, and manage adverse effects associated with novel therapies in patients treated for ovarian cancer
Ursula A. Matulonis, MD
Professor of Medicine, Harvard Medical School
Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Co-Leader, Ovarian Cancer SPORE grant
Co-Leader, Dana-Farber/Harvard Cancer Center GYN program
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Daiichi Sankyo, Day One Biopharmaceuticals, GSK, ImmunoGen, NextCure; Novartis; Daiichi Sankyo; Tango; Day One; GlaxoSmithKline; AbbVie; Immunogen; Whitehawk; Data Safety Monitoring Board: Symphogen; Mural Oncology; Daiichi Sankyo; MacroGenics
Bradley J. Monk, MD, FACS, FACOG
Professor, College of Medicine
University of Central Florida
Medical Director, Late-Phase Research Program
Florida Cancer Specialists and Research Institute
West Palm Beach, FL
Disclosures: Advisor, Consultant, Fee for Service Recipient: AbbVie, Alkermes, AstraZeneca, BioNTech SE, Corcept Therapeutics, DSI, Eisai, Genmab, Genmab/Seagen, Genmab/Seattle Genetics, GlaxoSmithKline, GOG Foundation, Gradalis, ImmunoGen, Incyte, Karyopharm Therapeutics, Lilly, Merck, Mersana, Mural, Myriad Genetics, Myriad Pharmaceuticals, Natera, Novartis, Novocure, Onco4[ST1.1], OncoC4, Panavance Therapeutics, Pharma&, ProfoundBio, Regeneron, Roche/Genentech, Sutro Biopharma, Tubulis GmbH, Verastem, Zentalis, Zymeworks; Speakers Bureau; AstraZeneca, Eisai, Immunogen/AbbVie, Lilly, Merck, tesaro/GSK; Grant/Research Funding: Advaxis, Amgen, Array BioPharma, AstraZeneca, Genentech, Immunogen, Janssen, Lilly, Morphotek, Novartis, NuCana, Pfizer, Regeneron, Tesaro
Ritu Salani, MD, MBA
Professor, Obstetrics and Gynecology
Director, Gynecologic Oncology
University of California
Los Angeles, CA
Disclosures: Consultant: Daiichi Sankyo; Advisory Board: AbbVie, Eisai, GSK, Merck, Pfizer, Regeneron
Oladapo Yeku, MD, PhD, FACP
Associate Professor, Harvard Medical School
Director of Translational Research, Gynecologic Oncology Program
Massachusetts General Hospital
Boston, MA
Disclosures: Advisory Board Member: HC Bioscience; Contracted Research: Ascendis Pharma, BioNTech, Immunocore Limited, Merck Sharp & Dohme, ProfoundBio
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here